Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAb 006-011 is an investigational monoclonal antibody candidate in the discovery stage, developed by MedAbome. It is designed to target multiple undisclosed tumor-associated antigens. MedAbome is exploring the candidate across several advanced therapeutic modalities, including antibody-drug conjugates (ADCs), radionuclide-drug conjugates (RDCs), and in vivo CAR-T/NK cell therapies. MAb 006-011 is being developed for the treatment of solid tumors and hematologic malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MAb 006-011.